1. Home
  2. AVTX vs VTGN Comparison

AVTX vs VTGN Comparison

Compare AVTX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • VTGN
  • Stock Information
  • Founded
  • AVTX 2011
  • VTGN 1998
  • Country
  • AVTX United States
  • VTGN United States
  • Employees
  • AVTX N/A
  • VTGN N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • VTGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVTX Health Care
  • VTGN Health Care
  • Exchange
  • AVTX Nasdaq
  • VTGN Nasdaq
  • Market Cap
  • AVTX 88.4M
  • VTGN 82.7M
  • IPO Year
  • AVTX 2015
  • VTGN N/A
  • Fundamental
  • Price
  • AVTX $7.35
  • VTGN $2.97
  • Analyst Decision
  • AVTX Strong Buy
  • VTGN
  • Analyst Count
  • AVTX 4
  • VTGN 0
  • Target Price
  • AVTX $33.00
  • VTGN N/A
  • AVG Volume (30 Days)
  • AVTX 54.4K
  • VTGN 180.4K
  • Earning Date
  • AVTX 03-28-2025
  • VTGN 02-13-2025
  • Dividend Yield
  • AVTX N/A
  • VTGN N/A
  • EPS Growth
  • AVTX N/A
  • VTGN N/A
  • EPS
  • AVTX N/A
  • VTGN N/A
  • Revenue
  • AVTX $820,000.00
  • VTGN $698,000.00
  • Revenue This Year
  • AVTX N/A
  • VTGN N/A
  • Revenue Next Year
  • AVTX N/A
  • VTGN N/A
  • P/E Ratio
  • AVTX N/A
  • VTGN N/A
  • Revenue Growth
  • AVTX N/A
  • VTGN N/A
  • 52 Week Low
  • AVTX $4.18
  • VTGN $2.22
  • 52 Week High
  • AVTX $34.46
  • VTGN $5.74
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 42.79
  • VTGN 56.23
  • Support Level
  • AVTX $7.42
  • VTGN $2.60
  • Resistance Level
  • AVTX $8.50
  • VTGN $3.04
  • Average True Range (ATR)
  • AVTX 0.64
  • VTGN 0.19
  • MACD
  • AVTX 0.02
  • VTGN -0.01
  • Stochastic Oscillator
  • AVTX 17.16
  • VTGN 74.00

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: